Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study
Njira L Lugogo, Praveen Akuthota, Kaharu Sumino, Autumn F Burnette, Sameer K Mathur, Andrew W Lindsley, Jean-Pierre Llanos, Claudio Marchese, Christopher S Ambrose, Benjamin Emmanuel · 2026
Read Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study by Njira L Lugogo, Praveen Akuthota, Kaharu Sumino, Autumn F Burnette, Sameer K Mathur, Andrew W Lindsley, Jean-Pierre Llanos, Claudio Marchese, Christopher S Ambrose, Benjamin Emmanuel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13519350.txt.
Description
Njira Lugogo and co-authors report real-world results for tezepelumab, a drug for severe asthma, in work dated two thousand twenty-six. Trials of such drugs often leave out key groups, such as Black patients, teens, and smokers. The PASSAGE study enrolled a broad United States mix with severe asthma that standard care failed to tame.
Two hundred eighty-six patients took the drug for twelve months in an open study with no placebo arm. Attack rates fell by seventy percent versus the prior year, and by half or more in every subgroup. Lung airflow rose as well, above all in patients whose blood held more of one marker cell type. The study argues the drug works across the full range of real patients.
Catalog record
| CREATOR | Njira L Lugogo, Praveen Akuthota, Kaharu Sumino, Autumn F Burnette, Sameer K Mathur, Andrew W Lindsley, Jean-Pierre Llanos, Claudio Marchese, Christopher S Ambrose, Benjamin Emmanuel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |